抗Nectin-4 ADC CRB-701眼部毒性:结合缘角膜营养不良与微囊样改变的病例系列
Combined limbal dysmaturation and microcyst like epithelial changes with corneal nerve alterations of a novel anti nectin-4-MMAE antibody drug conjugate
一项回顾性单中心病例系列报告了14例接受抗Nectin-4抗体药物偶联物CRB-701治疗的epithelial malignancies患者出现的角膜毒性事件。
Antibody-drug conjugates (ADCs) targeting Nectin cell adhesion molecule 4 (Nectin-4), a transmembrane protein frequently overexpressed in epithelial cancers, are rapidly emerging therapies with great clinical promise, but their ocular toxicity profiles remain incompletely characterized. We report the ocular surface adverse events of CRB-701, an investigational anti-Nectin-4 ADC with a monomethyl auristatin E (MMAE) payload, evaluated in a phase I trial (NCT06265727).
This retrospective, single-centre case series reports 14 consecutive patients (8 women, 6 men, median age 59 years) undergoing treatment with CRB-701 for epithelial malignancies (Supplementary Table 1). Prophylaxis consisted of preservative-free hyaluronic acid, and fluorometholone eye drops t.i.d., a cold eyelid mask during drug infusion and brimonidine eye drops b.i.d. from two days before to two weeks after each infusion. All patients underwent repeated standardized ophthalmological examinations; in vivo confocal microscopy (IVCM) was performed in selected cases to characterize epithelial abnormalities and corneal nerve involvement.
Data availability
Data available on reasonable request.
References
Gabison EE, Rousseau A, Labetoulle M, Gazzah A, Besse B. Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies. Prog Retin Eye Res. 2024;103:101302. https://doi.org/10.1016/j.preteyeres.2024.101302.
Nikanjam M, Pérez-Granado J, Gramling M, Larvol B, Kurzrock R. Nectin-4 expression patterns and therapeutics in oncology. Cancer Lett. 2025;622:217681. https://doi.org/10.1016/j.canlet.2025.217681.
Okumura N, Kagami T, Fujii K, Nakahara M, Koizumi N. Involvement of nectin-afadin in the adherens junctions of the corneal endothelium. Cornea. 2018;37:633–40. https://doi.org/10.1097/ICO.0000000000001526.
Kusanagi R, Umemoto T, Yamato M, Matsuzaki Y, Nishida K, Kobayashi Y, et al. Nectin-3 expression is elevated in limbal epithelial side population cells with strongly expressed stem cell markers. Biochem Biophys Res Commun. 2009;389:274–8. https://doi.org/10.1016/j.bbrc.2009.08.130.
Zhang J, Li M, Li W, Yang Y, Wu G, Guo P, et al. Mechanistic insights into anti-nectin4-VcMMAE-induced ocular toxicity: from cellular uptake pathways to molecular modification. Int J Mol Sci. 2025;26:4996 https://doi.org/10.3390/ijms26114996.
Funding
This study received no funding.
Author information
Authors and Affiliations
Service d’Ophtalmologie, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre, France
Marwa Deiri, Rafael Boucher, Marc Labetoulle & Antoine Rousseau
Département d’innovation thérapeutique, Institut Gustave Roussy, Villejuif, France
Cédric Pobel, Jacopo Uliano, Yohann Loriot & Kaissa Ouali
Service d’Ophtalmologie, Hôpital National de la Vision des 15-20, IHU FOReSight, Paris, France
Marc Labetoulle & Antoine Rousseau
Center for Immunology of Viral Infections and Autoimmune Diseases, Institut Nationale de la Santé et de la Rercherche Medicale (INSERM), UMR 1184, IDMIT, Université Paris Saclay, Le Kremlin Bicêtre, France
Marc Labetoulle & Antoine Rousseau
Authors
- Marwa Deiri
- Rafael Boucher
- Cédric Pobel
- Jacopo Uliano
- Yohann Loriot
- Kaissa Ouali
- Marc Labetoulle
- Antoine Rousseau
Contributions
MD, RB, ML, and AR contributed to study conception and design. MD, RB, JU, CP, YL, KO, ML, and AR contributed to data collection. MD, RB, ML, and AR contributed to analysis and interpretation of results. MD, RB, JU, CP, YL, KO, ML, and AR wrote and edited the manuscript. RB and AR proofread and edited the manuscript. All authors read and approved the final manuscript.
Corresponding author
Correspondence to Marwa Deiri.
Ethics declarations
Competing interests
MD, RB, and JU: nothing to declare. CP reports receiving honoraria from Merck and Johnson & Johnson, as well as travel grants and invitations from Amgen, AstraZeneca, Bayer, Eisai, Ipsen, Janssen-Cilag, MSD, Pfizer, Sandoz, Sanofi, Seagen France and Vifor. As part of the Drug Development Department (DITEP), he reports serving as a principal or sub-investigator of clinical trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Astra Zeneca Ab, Astra Zeneca, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Casi Pharmaceuticals, Inc, Cato Research, Celgene Corporation, Cellcentric, Chugai Pharmaceutical Co, Corbus, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, EverImmune, Exelixis, Faron Pharmaceuticals Ltd, Foghorn Therapeutics Inc, Forma Tharapeutics, Gamamabs, Genentech, Genmab, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, IGM Biosciences, Imcheck Therapeutics, Incyte Corporation, Innate Pharma, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Janssen R&D LLC, johnson & johnson, K-Group Beta, Kinnate Biopharma, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merus, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Nuvalent, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Phio Pharmaceuticals Corp, Pierre Fabre Medicament, Pyramid Bioscience, Regeneron Pharmaceuticals, Relay Therapeutics, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Transgene S.A, Turning Point Therapeutics and Xencor. He also reports research grants from AstraZeneca, BMS, Boehringer Ingelheim, Celsius, EIT Philips, GSK, IDERA, INCA, Janssen, Lombard, MedImmune, Merck, Pierre Fabre, Roche, Sanofi and Servier, and non-financial support (drug supplied) from AstraZeneca, BMS, Boehringer Ingelheim, GSK, Idera, MedImmune, Merck, NH Theraguix and Roche. YL reports research funding from Astellas, Amgen, OBS and PMV. He reports consulting or advisory roles for Janssen, MSD, Pfizer, Astellas, Roche and AstraZeneca. He also reports receiving honoraria from Janssen, MSD, Pfizer, Astellas, Roche and AstraZeneca, as well as travel, accommodation or expense support from Janssen, MSD, Pfizer, Astellas and AstraZeneca. KO reports serving as a sub-investigator for the clinical trial of CRB 701. ML serves as an occasional consultant for GSK, Novartis, and AbbVie. AR serves as an occasional consultant for GSK, Novartis, AbbVie, AstraZeneca, Genmab. The other authors have no conflict of interest in relationship with this study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Deiri, M., Boucher, R., Pobel, C. et al. Combined limbal dysmaturation and microcyst like epithelial changes with corneal nerve alterations of a novel anti nectin-4-MMAE antibody drug conjugate. Eye (2026). https://doi.org/10.1038/s41433-026-04976-2
Received: 16 June 2026
Revised: 19 September 2026
Accepted: 24 September 2026
Published: 08 October 2026
Version of record: 08 October 2026
DOI: https://doi.org/10.1038/s41433-026-04976-2
来源:Nature 健康护理主题 · nature.com